Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. (Q54665285)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

pattern recognition

1 reference

based on heuristic

inferred from title

Per Soelberg Sørensen

3

object named as

Per Soelberg Sørensen

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

author name string

Christian Enevold

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Annette B Oturai

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Lars P Ryder

4

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Nils Koch-Henriksen

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Klaus Bendtzen

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

publication date

1 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

16

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

8

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

942-949

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Clinical characteristics of responders to interferon therapy for relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Follicular B helper T cells in antibody responses and autoimmunity.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Regulation of lung injury and repair by Toll-like receptors and hyaluronan

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

High mobility group box 1 protein interacts with multiple Toll-like receptors

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptors: critical proteins linking innate and acquired immunity

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

dbSNP: the NCBI database of genetic variation

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

PowerMarker: an integrated analysis environment for genetic marker analysis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Performing the exact test of Hardy-Weinberg proportion for multiple alleles

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

The genetic epidemiology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Sex ratio of multiple sclerosis in Canada: a longitudinal study

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptor stimulation as a third signal required for activation of human naive B cells.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptor heterodimer variants protect from childhood asthma

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells.

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Analysis of an IFN- gamma gene (IFNG) Polymorphism in Multiple Sclerosis in Europe: Effect of Population Structure on Association with Disease

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Interferon-? gene polymorphism-associated risk for multiple sclerosis in sardinia

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Letter to the editor

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1177%2F1352458510373264

21 January 2018

Identifiers

10.1177/1352458510373264

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20595247

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54665285&oldid=1511019526"